CA Patent

CA3174550A1 — Medicament containing sofpironium bromide

Assigned to Kaken Pharmaceutical Co Ltd · Expires 2021-09-10 · 5y expired

What this patent protects

Provided is a uniformly dispersed anhydrous formulation or low-water-content formulation having a water content of not more than 5%. This formulation is a drug formulation for topical application to the surface of the human body and exhibits an inhibited decline in viscosity duri…

USPTO Abstract

Provided is a uniformly dispersed anhydrous formulation or low-water-content formulation having a water content of not more than 5%. This formulation is a drug formulation for topical application to the surface of the human body and exhibits an inhibited decline in viscosity during long-term storage. The formulation contains sofpironium bromide, a water-soluble polymer, and ethanol and has a pH not greater than 5.2.

Drugs covered by this patent

Patent Metadata

Patent number
CA3174550A1
Jurisdiction
CA
Classification
—
Expires
2021-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Kaken Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.